Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...

Treatment with an aromatase inhibitor, either alone or in combination with growth hormone (GH), slowed bone advancement and enhanced adult height in mid-pubertal boys with a short predicted adult ...

Increase in blood pressure in patients with metastatic kidney cancer treated with combination checkpoint inhibitor and vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.

DEAR DR. ROACH: I am 78 years old. Breast cancer runs in my family, and I am one of the lucky ones who had a lump that was caught early through an annual mammogram. I had a partial mastectomy, which ...

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine ...